If you are not yet aware, the DEA recently made marijuana extracts, including the non-psychoactive class of biomolecules within marijuana known as cannabinoids (CBD), schedule 1 drugs.
This means they will all now be classified alongside heroin, LSD, cocaine, and ecstasy, as possessing a high potential of abuse, no currently accepted medical use in treatment in the U.S., and lacking safety, even under medical supervision. READ MORE…
HOLD ON…The DEA’s notice in the Federal Register on Wednesday, however, sent that entire industry sector into turmoil.
The DEA’s attempt to criminalize the status of cannabidiol (CBD) earlier this week has thrown the cannabis industry into an uproar. Hundreds of thousands of patients around the country rely on non-psychoactive CBD products to manage pain, inflammation, seizures, and other medical conditions. Hemp-derived CBD oil was, and continues to be, sold openly in American markets. READ MORE>>>